High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 7097 - 7099
Main Authors Keller, Alana, Perez De Acha, Olivia, Reiman, Lauren T, Walker, Zachary J, Jayabalan, David S, Niesvizky, Ruben, Forsberg, Peter A, Kim, Peter, Bisht, Kamlesh, Wang, Hongfang, van de Velde, Helgi, Sherbenou, Daniel W.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-169072